The chemical class known as CRP2 Inhibitors consists of compounds that target the Cysteine and Glycine-Rich Protein 2 (CRP2), a protein implicated in various cellular functions, notably in muscle development and cytoskeletal organization. These inhibitors are not directly aimed at CRP2 but are designed to affect the pathways and processes in which CRP2 is involved. The primary mechanism by which these compounds function is through the modulation of signaling pathways and cellular processes that CRP2 influences, including muscle cell differentiation, cytoskeletal dynamics, and cardiac function. By targeting specific enzymes, kinases, and signaling cascades, CRP2 inhibitors can alter the functional dynamics of CRP2 within cells, thereby modulating its activity in various physiological processes.
The development of CRP2 inhibitors is a sophisticated approach that takes into account the multifaceted roles of CRP2 in cell biology. Given CRP2's involvement in muscle and cardiac development, as well as its interaction with the actin cytoskeleton, these inhibitors operate by either disrupting CRP2's ability to interact with other cellular proteins or by altering downstream signaling cascades and cellular mechanisms that CRP2 influences. This is achieved through various molecular actions, such as kinase inhibition, modulation of intracellular signaling molecules, alteration of enzymatic activity, and interference with specific molecular pathways involved in cell differentiation, growth, and response to mechanical stress. The diversity of these inhibitors reflects the complexity of CRP2's role in cellular functions, underlining the intricate network of molecular interactions and pathways essential for normal cellular development, particularly in muscle tissue and the cardiovascular system. In summary, CRP2 inhibitors represent a class of compounds that play a crucial role in exploring the biological functions of CRP2. Their ability to modulate key aspects of cellular signaling and development highlights the critical role of CRP2 in these processes. As research tools, these inhibitors provide valuable insights into the mechanisms through which CRP2 operates in cellular environments, enhancing our understanding of muscle development, cytoskeletal organization, and cardiac health. This class of inhibitors, therefore, plays an important role in advancing our knowledge of the fundamental mechanisms of cellular function and the dynamics of CRP2 in physiological and developmental processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor. Inhibiting ROCK could possibly inhibit CSRP2 by disrupting actin cytoskeleton organization. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin inhibits myosin II. This inhibition could possibly affect muscle cell contraction and inhibit CSRP2's role in muscle cell function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits myosin light chain kinase (MLCK). Inhibiting MLCK could possibly affect cytoskeletal dynamics, potentially inhibiting CSRP2-mediated processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. By affecting PI3K signaling, it could possibly inhibit pathways involved in cell growth and differentiation where CSRP2 plays a role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK. Inhibition of p38 MAPK could possibly affect signaling pathways related to stress response and muscle development, thereby inhibiting CSRP2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. It could possibly disrupt signaling pathways crucial for cell differentiation and survival, thereby inhibiting CSRP2's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth. Inhibiting mTOR could possibly impact muscle cell development and function, potentially inhibiting CSRP2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK in the MAPK/ERK pathway. Inhibiting this pathway could possibly affect CSRP2's role in cellular signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor. Its action could possibly disrupt several signaling pathways, thereby inhibiting CSRP2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, part of the MAPK pathway. Inhibiting JNK could possibly influence CSRP2's role in cellular stress response and development. | ||||||